Diss. (sammanfattning) Stockholm : Karolinska institutet, 2002. / Härtill 4 uppsatser.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 4 uppsatser.

Thesis (Ph. D.)--University of Washington, 1996. / Vita. Includes bibliographical references (leaves [115]-121).

Orientador: Maria Marluce dos Santos Vilela / Dissertação (mestrado) - Universidade Estadual de Campinas. Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-15T09:35:25Z (GMT). No. of bitstreams: 1 Ramalho_VanessaDomingues_M.pdf: 1157730 bytes, checksum: 0cd719050713e1b2340be47d4d5f5b38 (MD5) Previous issue date: 2010 / Resumo: A agamaglobulinemia ligada ao X (XLA; OMIM#300755) é uma imunodeficiência primária humoral caracterizada por um bloqueio na diferenciação dos linfócitos B na medula óssea, levando à profunda hipogamaglobulinemia e reduzido número ou ausência de células B periféricas. Os pacientes com XLA são susceptíveis a infecções recorrentes por bactérias encapsuladas e enterovírus devido à deficiência de anticorpos. Mutações no gene codificante da tirosina quinase de Bruton (Btk) são responsáveis pela doença. Btk é uma tirosina quinase citoplasmática da família Tec importante no desenvolvimento, na diferenciação e na sinalização dos linfócitos B. A detecção de mutações no gene btk possibilita o diagnóstico definitivo de XLA. O objetivo deste estudo foi identificar e caracterizar mutações em btk. Foram incluídos 6 pacientes conforme os critérios do PAGID e ESID: indivíduos do sexo masculino com menos de 2% de linfócitos B periféricos, hipogamaglobulinemia e história de infecções bacterianas de repetição. A triagem de mutações foi realizada com a técnica de SSCP e possíveis mutações foram confirmadas por seqüenciamento. A expressão de Btk nos pacientes e mães foi avaliada em monócitos por citometria de fluxo. Dentre os pacientes analisados as principais manifestações clínicas foram as infecções do trato respiratório. Todos tiveram início dos sintomas durante o primeiro ano de vida, linfócitos B periféricos abaixo de 2% e hipogamaglobulinemia anterior ao início da terapia de reposição de imunoglobulinas. Foram identificadas cinco mutações em btk, três novas (p.Ala347fsX55, p.I355T e p.Thr324fsX24) e duas já descritas na literatura (p.Q196X e p.E441X). A detecção das mutações nos pacientes permitiu a análise mutacional de mães, avós e tias maternas. Três mães e uma avó foram confirmadas portadoras de XLA. Em adição, os valores de expressão de Btk obtidos mostraram deficiência da proteína (4,5% a 65,2%) nos pacientes e um padrão bimodal de expressão de Btk foi observado nas mães, indicando o estado de portadora de XLA. Em um dos pacientes não foi identificada mutação, entretanto a expressão de Btk mostrou-se reduzida. O uso combinado da análise genética e da avaliação da expressão de Btk por citometria de fluxo possibilitou o diagnóstico definitivo de XLA e a identificação de portadoras da doença. / Abstract: X-linked agammaglobulinemia (XLA; OMIM# 300755) is a primary humoral immunodeficiency characterized by a block in early B cell differentiation, leading to profound hypogammaglobulinemia and few or no circulating B cells. Patients with XLA are susceptible to recurrent infections by encapsulated bacteria and enteroviruses due to antibody deficiency. Mutations in the Bruton tyrosine kinase (Btk) gene have been identified as responsible for XLA. Btk is a cytoplasmic tyrosine kinase of the Tec family important in B-lymphocyte development, differentiation, and signaling. Detection of a btk mutation allows definitive diagnosis of XLA. The aim of this study was to identify and characterize mutations in btk. Six patients were included according to the criteria of PAGID and ESID: males with less than 2% of circulating B cells, hypogammaglobulinemia and a history of recurrent bacterial infections. Mutation screening was performed with SSCP technique and possible mutations were confirmed by sequencing. Expression of Btk protein in patients and mothers was assessed in monocytes by flow cytometry. The major clinical manifestations among patients were respiratory tract infections. All had onset of symptoms during the first year of life, circulating B cells below 2% and hypogammaglobulinemia before the start of immunoglobulin replacement therapy. We identified five mutations in btk, three novel (p.Ala347fsX55, p.I355T and p.Thr324fsX24) and two recurrent mutations (p.Q196X and p.E441X). The btk mutations detection in patients enabled the screening of mothers, grandmothers and maternal aunts. Three mothers and one grandmother were confirmed XLA carriers. In addition, flow cytometric evaluation of Btk expression in monocytes revealed that Btk deficiency (4,5% a 65,2%) was present in patients and a bimodal pattern of Btk expression was observed in mothers, indicating that they were XLA carriers. In one patient no mutation was identified, but his Btk expression was reduced. The combined use of genetic analysis and flow cytometric assay of Btk protein expression allowed the definitive diagnosis of XLA and its carriers detection. / Mestrado / Saude da Criança e do Adolescente / Mestre em Saude da Criança e do Adolescente

Orientador: Maria Marluce dos Santos Vilela / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-24T17:02:47Z (GMT). No. of bitstreams: 1 Ramalho_VanessaDomingues_D.pdf: 1441004 bytes, checksum: a45d3f4f8825288e2959115ef25fc13a (MD5) Previous issue date: 2014 / Resumo: A agamaglobulinemia ligada ao X (XLA; OMIM#300755) é caracterizada por um bloqueio na diferenciação dos linfócitos B na medula óssea, levando à profunda hipogamaglobulinemia e reduzido número ou ausência de linfócitos B periféricos. Os pacientes são susceptíveis a infecções recorrentes por bactérias encapsuladas e enterovírus. XLA é causada por mutações no gene da tirosina quinase de Bruton (BTK). Contudo, não há estudos de relação entre expressão protéica e o tipo de mutação, nem sobre as conseqüências da retenção intracelular do excesso de proteínas mal formadas. Os objetivos deste trabalho foram avaliar a expressão de BTK e sua relação com o tipo de mutação em pacientes com XLA, assim como verificar suas conseqüências nos sensores de estresse do retículo endoplasmático. O diagnóstico de XLA foi baseado em infecções recorrentes, níveis significativamente reduzidos de IgM, IgG e IgA, linfócitos B circulantes <2% e mutação identificada no gene BTK. A expressão dos transcritos de BTK foi avaliada por PCR quantitativo em tempo real em oito pacientes XLA e oito controles. Pela mesma técnica, foi avaliada a expressão de 10 genes do estresse do retículo endoplasmático em seis pacientes e seis controles. Foram caracterizadas quatro mutações missense, uma mutação nonsense, dois frameshifts e um defeito em sítio de splicing. As mutações do tipo nonsense, frameshift e defeito em sítio de splicing levaram à formação de stop codon prematuro. Foi detectado um perfil de expressão de BTK diferenciado nos pacientes com mutações com stop codon prematuro em comparação aos pacientes com mutações missense e controles saudáveis. Especificamente, os pacientes com mutações com stop codon prematuro apresentaram redução da expressão de BTK (P = 0,004). No entanto, verificamos que as mutações missense não afetaram a expressão de BTK. Por meio de imunocitoquímica, encontramos que as mutações com stop codon prematuro levaram à deficiência da expressão da proteína BTK e as do tipo missense resultaram na localização anormal da proteína no citoplasma celular, o que evidencia a síntese de proteína não funcional. Os pacientes com XLA apresentaram expressão aumentada do marcador de estresse do retículo endoplasmático XBP1 (P = 0,002). Em conclusão, a quantificação da expressão de mRNA para BTK é uma ferramenta para diferenciar as conseqüências mutacionais em pacientes com XLA. Ela também pode contribuir para o estudo de transcritos em outras doenças genéticas com diferentes tipos de mutação. Este é o primeiro relato de estresse do retículo endoplasmático na agamaglobulinemia ligada ao X / Abstract: X-linked agammaglobulinemia (XLA, OMIM # 300755) is characterized by a block in differentiation of B lymphocytes in the bone marrow, leading to profound hypogammaglobulinemia and few or no peripheral B lymphocytes. Patients are susceptible to recurrent infections by encapsulated bacteria and enteroviruses. XLA is caused by mutations in the Bruton tyrosine kinase gene (BTK). However, there have been no studies on the relationship between protein expression and the type of mutation, nor on the consequences of the disruption of protein folding that results in intracellular retention. The objectives of this study were to evaluate BTK expression and its mutation type in patients with XLA, as well as to verify their consequences on the endoplasmic reticulum stress sensors. The XLA diagnosis was based on recurrent infections, significantly reduced levels of IgM, IgG and IgA, circulating B lymphocytes <2% and BTK gene mutation identified. The expression of BTK transcripts was assessed by quantitative real-time PCR in eight XLA patients and eight control subjects. By the same technique, the expression of 10 endoplasmic reticulum stress genes was measured in six patients and six controls. Four missense mutations, one nonsense mutation, two frameshifts and a splice site defect were characterized. Mutations of the nonsense type, frameshift and splice site defect led to a premature stop codon formation. A differential profile of expression of BTK was detected in patients with mutations that led to a premature stop codon compared to patients with missense mutations and healthy controls. Specifically, patients with mutations resulting in a premature stop codon exhibited reduced expression of BTK gene (P = 0.004). However, it was found that missense mutations did not affect BTK expression. By immunocytochemistry, we found that mutations with a premature stop codon impaired expression of BTK protein and that missense mutations led to an abnormal localization of the protein in the cell cytoplasm, showing the synthesis of a non-functional protein. Patients with XLA showed increased expression of the endoplasmic reticulum stress marker XBP1 (P = 0.002). In conclusion, the quantification of mRNA expression for BTK is a tool to differentiate mutational consequences in patients with XLA. It can also contribute to the study of transcripts in other genetic diseases with different types of mutation. This is the first report on endoplasmic reticulum stress in X-linked agammaglobulinemia / Doutorado / Saude da Criança e do Adolescente / Doutora em Ciências

Pancreatic ductal adenocarcinoma (PDAC) is a serious oncological disease, which ranks among cancers with the worst prognosis and a three-year life expectancy of 10%. Ex-vivo organoid cultures derived from cancer tissue are popular and reliable research models, which reflect the morphology and histology of the original tissue. Genetic background leading to development PDAC confer typical alterations in genes KRAS, TP53, SMAD4 a CDKN2A. The aim of this thesis was to determine mutations present in organoid cultures derived from human PDAC. We used online genomic databases to estimate specific mutations typical for PDAC. Based on that research we designed protocols for the detection of PDAC genetic alterations and optimized those methods using cultured cells. We applied the approach on primary ex- vivo organoids derived from surgical cancer specimens and detected mutations in KRAS, TP53, SMAD4, or deletion of exons in CDKN2A. Alternatively, we proposed improvements for the analysis of genetic background in PDAC. The data obtained within this thesis will be used for the stratification of metabolomics and biochemical analyses further in the project.

No description available.

No description available.

Fu Zhenming. / Thesis submitted in: December 2003. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (leaves 138-162). / Abstracts in English and Chinese. / List of abbreviations --- p.i / Abstract (in English) --- p.ii / 摘要（中文） --- p.iii / Acknowledgement --- p.iv / Chapter Chapter 1. --- Introduction and Objectives of Study --- p.1 / Chapter 1.1 --- Hepatocellular carcinoma in general --- p.2 / Chapter 1.1.1 --- "Epidemiology, risk factors" --- p.2 / Chapter 1.1.2 --- Pathology and staging --- p.4 / Chapter 1.1.3 --- Treatment --- p.6 / Chapter 1.1.4 --- Improvement of early detection and treatment of HCC --- p.7 / Chapter 1.2 --- General aspects of mitochondria and mitochondrial DNA (mtDNA) --- p.10 / Chapter 1.2.1 --- Structure and dynamics of mitochondria --- p.10 / Chapter 1.2.1.1 --- General introduction of mitochondria --- p.10 / Chapter 1.2.1.2 --- Respiration chain of mitochondria --- p.11 / Chapter 1.2.2 --- The mitochondrial genome --- p.14 / Chapter 1.2.2.1 --- Strucure --- p.14 / Chapter 1.2.2.2 --- Genes for structure proteins --- p.16 / Chapter 1.2.2.3 --- Genes for translation --- p.17 / Chapter 1.2.2.4 --- Imported proteins and RNAs --- p.17 / Chapter 1.2.3 --- Mitochondrial DNA maintenance --- p.19 / Chapter 1.2.4 --- Mitochondrial DNA replication --- p.25 / Chapter 1.2.5 --- Mitochondrial DNA transcription --- p.30 / Chapter 1.2.6 --- Mitochondrial DNA translation --- p.32 / Chapter 1.3 --- MtDNA diseases --- p.35 / Chapter 1.4 --- MtDNA mutation and HCC --- p.35 / Chapter 1.5 --- Aims of the study --- p.39 / Chapter Chapter 2. --- Materials and Methods --- p.41 / Chapter 2.1 --- Materials --- p.42 / Chapter 2.1.1 --- Chemicals --- p.42 / Chapter 2.1.2 --- Primers --- p.42 / Chapter 2.1.3 --- Enzymes --- p.45 / Chapter 2.1.4 --- Cell line --- p.45 / Chapter 2.1.5 --- Collection of specimens --- p.46 / Chapter 2.2 --- Methodology --- p.47 / Chapter 2.2.1 --- "DNA extraction from hcc tissues, cell line Hep3B and PBMCs" --- p.47 / Chapter 2.2.1.1 --- DNA extraction from HCC tissues --- p.47 / Chapter 2.2.1.2 --- DNA extraction from cell line Hep3B --- p.49 / Chapter 2.2.1.3 --- DNA extraction from and PBMCs --- p.50 / Chapter 2.2.1.3.1 --- Preparation of PBMCs --- p.50 / Chapter 2.2.1.3.2 --- DNA extraction from and PBMCs --- p.51 / Chapter 2.2.2 --- Detection of mt whole genome mutation by direct sequencing --- p.51 / Chapter 2.2.2.1 --- Design of mtDNA primers --- p.51 / Chapter 2.2.2.2 --- PCR amplification of the whole mt genome --- p.51 / Chapter 2.2.2.3 --- Direct sequencing of the whole mt genome --- p.52 / Chapter 2.2.2.3.1 --- Primer used in sequencing --- p.52 / Chapter 2.2.2.3.2 --- Purification of the PCR products of the whole mt genome --- p.53 / Chapter 2.2.2.3.3 --- Dye terminator cycle sequencing reaction --- p.53 / Chapter 2.2.2.3.4 --- Purification of extension products --- p.54 / Chapter 2.2.3 --- Detection of mtDNA control region mutation --- p.55 / Chapter 2.2.3.1 --- PCR amplification of D310 in the mtDNA control region --- p.55 / Chapter 2.2.3.2 --- Screening of D310 mutation by PFLDA --- p.55 / Chapter 2.2.3.2.1 --- Making 8% denatured gel mixture --- p.55 / Chapter 2.2.3.2.2 --- Setting up and Pouring the denatured gel --- p.56 / Chapter 2.2.3.2.4 --- Preparing and Loading the PCR products --- p.57 / Chapter 2.2.3.2.5 --- Electrophoresis --- p.57 / Chapter 2.2.3.2.6 --- "Gel fixing, silver staining and color development " --- p.58 / Chapter 2.2.3.3 --- Direct sequencing of D310 in the mtDNA control region --- p.59 / Chapter 2.2.4 --- Detection of mt DNA coding region mutation --- p.60 / Chapter 2.2.4.1 --- PCR amplification of the 5 respiratory chain subunit genes --- p.60 / Chapter 2.2.4.2 --- Restriction enzyme digestion of 5 genes in mtDNA coding region --- p.60 / Chapter 2.2.4.3 --- Screening of mtDNA coding region mutation by SSCP --- p.61 / Chapter 2.2.4.3.1 --- Making 6% 49:1 acrylamide/Bis SSCP gel mixture --- p.61 / Chapter 2.2.4.3.2 --- "Setting up the SSCP gel, loading sample, fixing, staining and developing of the gel " --- p.62 / Chapter 2.2.4.4 --- Sequencing conformation of the mtDNA coding region mutation --- p.62 / Chapter 2.2.5 --- Statistics --- p.63 / Chapter 2.2.5.1 --- The chi-square test --- p.63 / Chapter 2.2.5.2 --- The Friedman test --- p.63 / Chapter 2.2.5.3 --- Wilcoxon signed ranks test --- p.63 / Chapter Chapter 3. --- Results --- p.64 / Chapter 3.1 --- Detection mt DNA whole genome mutation --- p.65 / Chapter 3.1.1 --- Identification of mtDNA whole genome by direct sequencing --- p.65 / Chapter 3.2 --- Detection mt DNA D-loop mutation --- p.76 / Chapter 3.2.1 --- Screening of C-tract alteration in HCC tissus by PCR fragments length detection assay (PFLDA) --- p.76 / Chapter 3.2.2 --- Screening of coding region alteration in HCC tissues by SSCP --- p.77 / Chapter 3.2.2.1 --- Identification of C-tract alterations in HCC and non-tumorous tissues by direct sequencing --- p.77 / Chapter 3.2.3 --- Identification of C-tract alterations by direct sequencing --- p.82 / Chapter 3.2.3.1 --- Identification of C-tract alterations in HCC tissues by direct sequencing --- p.82 / Chapter 3.2.3.2 --- Identification of C-tract alteration in PBMC of normal subjects by direct sequencing --- p.82 / Chapter 3.2.3.3 --- Identification of C-tract alteration in PBMC of HCC patients by direct sequencing --- p.82 / Chapter 3.2.4 --- Statistics of the analysis of C-tract alterations --- p.82 / Chapter 3.3 --- Detection mt DNA mutation in the coding region --- p.87 / Chapter Chapter 4. --- Discussion --- p.98 / Chapter 4.1 --- Detection mtDNA whole genome mutation --- p.99 / Chapter 4.2 --- Detection mtDNA D-loop mutation --- p.107 / Chapter 4.3 --- Detection mtDNA mutation in the coding region --- p.119 / Chapter 4.4 --- Possible mechanisms of mtDNA mutation in HCC carcinogenesis --- p.125 / Chapter 4.5 --- Proposals for prospective studies --- p.126 / Chapter 4.5.1 --- Function of C7 in D310 --- p.128 / Chapter 4.5.2 --- Function changes of mtDNA coding region mutation --- p.130 / Chapter 4.5.3 --- Detection of D310 C-tract mutation in patients' plasma --- p.131 / Chapter 4.5.4 --- Relationship between nMSl and mtMSI --- p.132 / Chapter 4.6 --- Summary --- p.134 / References --- p.137

Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 7 uppsatser.